Cargando…
CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease
Metabolic dysfunction-associated fatty liver disease (MAFLD), previously called metabolic nonalcoholic fatty liver disease, is the most prevalent chronic liver disease worldwide. The multi-factorial nature of MAFLD severity is delineated through an intricate composite analysis of the grade of activi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661153/ https://www.ncbi.nlm.nih.gov/pubmed/37985560 http://dx.doi.org/10.1186/s41747-023-00387-0 |
_version_ | 1785148456462974976 |
---|---|
author | Hu, Na Yan, Gang Tang, Maowen Wu, Yuhui Song, Fasong Xia, Xing Chan, Lawrence Wing-Chi Lei, Pinggui |
author_facet | Hu, Na Yan, Gang Tang, Maowen Wu, Yuhui Song, Fasong Xia, Xing Chan, Lawrence Wing-Chi Lei, Pinggui |
author_sort | Hu, Na |
collection | PubMed |
description | Metabolic dysfunction-associated fatty liver disease (MAFLD), previously called metabolic nonalcoholic fatty liver disease, is the most prevalent chronic liver disease worldwide. The multi-factorial nature of MAFLD severity is delineated through an intricate composite analysis of the grade of activity in concert with the stage of fibrosis. Despite the preeminence of liver biopsy as the diagnostic and staging reference standard, its invasive nature, pronounced interobserver variability, and potential for deleterious effects (encompassing pain, infection, and even fatality) underscore the need for viable alternatives. We reviewed computed tomography (CT)-based methods for hepatic steatosis quantification (liver-to-spleen ratio; single-energy “quantitative” CT; dual-energy CT; deep learning-based methods; photon-counting CT) and hepatic fibrosis staging (morphology-based CT methods; contrast-enhanced CT biomarkers; dedicated postprocessing methods including liver surface nodularity, liver segmental volume ratio, texture analysis, deep learning methods, and radiomics). For dual-energy and photon-counting CT, the role of virtual non-contrast images and material decomposition is illustrated. For contrast-enhanced CT, normalized iodine concentration and extracellular volume fraction are explained. The applicability and salience of these approaches for clinical diagnosis and quantification of MAFLD are discussed. Relevance statement CT offers a variety of methods for the assessment of metabolic dysfunction-associated fatty liver disease by quantifying steatosis and staging fibrosis. Key points • MAFLD is the most prevalent chronic liver disease worldwide and is rapidly increasing. • Both hardware and software CT advances with high potential for MAFLD assessment have been observed in the last two decades. • Effective estimate of liver steatosis and staging of liver fibrosis can be possible through CT. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-10661153 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-106611532023-11-21 CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease Hu, Na Yan, Gang Tang, Maowen Wu, Yuhui Song, Fasong Xia, Xing Chan, Lawrence Wing-Chi Lei, Pinggui Eur Radiol Exp Narrative Review Metabolic dysfunction-associated fatty liver disease (MAFLD), previously called metabolic nonalcoholic fatty liver disease, is the most prevalent chronic liver disease worldwide. The multi-factorial nature of MAFLD severity is delineated through an intricate composite analysis of the grade of activity in concert with the stage of fibrosis. Despite the preeminence of liver biopsy as the diagnostic and staging reference standard, its invasive nature, pronounced interobserver variability, and potential for deleterious effects (encompassing pain, infection, and even fatality) underscore the need for viable alternatives. We reviewed computed tomography (CT)-based methods for hepatic steatosis quantification (liver-to-spleen ratio; single-energy “quantitative” CT; dual-energy CT; deep learning-based methods; photon-counting CT) and hepatic fibrosis staging (morphology-based CT methods; contrast-enhanced CT biomarkers; dedicated postprocessing methods including liver surface nodularity, liver segmental volume ratio, texture analysis, deep learning methods, and radiomics). For dual-energy and photon-counting CT, the role of virtual non-contrast images and material decomposition is illustrated. For contrast-enhanced CT, normalized iodine concentration and extracellular volume fraction are explained. The applicability and salience of these approaches for clinical diagnosis and quantification of MAFLD are discussed. Relevance statement CT offers a variety of methods for the assessment of metabolic dysfunction-associated fatty liver disease by quantifying steatosis and staging fibrosis. Key points • MAFLD is the most prevalent chronic liver disease worldwide and is rapidly increasing. • Both hardware and software CT advances with high potential for MAFLD assessment have been observed in the last two decades. • Effective estimate of liver steatosis and staging of liver fibrosis can be possible through CT. GRAPHICAL ABSTRACT: [Image: see text] Springer Vienna 2023-11-21 /pmc/articles/PMC10661153/ /pubmed/37985560 http://dx.doi.org/10.1186/s41747-023-00387-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Narrative Review Hu, Na Yan, Gang Tang, Maowen Wu, Yuhui Song, Fasong Xia, Xing Chan, Lawrence Wing-Chi Lei, Pinggui CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease |
title | CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease |
title_full | CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease |
title_fullStr | CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease |
title_full_unstemmed | CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease |
title_short | CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease |
title_sort | ct-based methods for assessment of metabolic dysfunction associated with fatty liver disease |
topic | Narrative Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661153/ https://www.ncbi.nlm.nih.gov/pubmed/37985560 http://dx.doi.org/10.1186/s41747-023-00387-0 |
work_keys_str_mv | AT huna ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease AT yangang ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease AT tangmaowen ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease AT wuyuhui ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease AT songfasong ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease AT xiaxing ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease AT chanlawrencewingchi ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease AT leipinggui ctbasedmethodsforassessmentofmetabolicdysfunctionassociatedwithfattyliverdisease |